Marinus Pharmaceuticals’ (MRNS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Tuesday, Benzinga reports. The brokerage currently has a $27.00 price objective on the biopharmaceutical company’s stock.

Several other research firms also recently issued reports on MRNS. Cantor Fitzgerald reissued an overweight rating and issued a $28.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Robert W. Baird restated a neutral rating on shares of Marinus Pharmaceuticals in a report on Tuesday. StockNews.com downgraded Marinus Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, March 6th. Oppenheimer reissued a market perform rating and issued a $9.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Finally, Royal Bank of Canada reiterated a sector perform rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Hold and an average target price of $18.21.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.20 on Tuesday. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. The firm’s 50-day moving average price is $8.89 and its 200-day moving average price is $8.50. The firm has a market capitalization of $65.92 million, a P/E ratio of -0.46 and a beta of 0.91. Marinus Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). The firm had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same period last year, the company posted ($0.76) earnings per share. Equities research analysts anticipate that Marinus Pharmaceuticals will post -2.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNS. Nuveen Asset Management LLC lifted its stake in shares of Marinus Pharmaceuticals by 1.1% during the 4th quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock valued at $1,519,000 after buying an additional 1,475 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Marinus Pharmaceuticals by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 2,281 shares in the last quarter. Deutsche Bank AG boosted its stake in Marinus Pharmaceuticals by 14.7% in the 3rd quarter. Deutsche Bank AG now owns 25,961 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 3,321 shares during the period. Tower Research Capital LLC TRC grew its holdings in Marinus Pharmaceuticals by 94.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 7,541 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 3,661 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Marinus Pharmaceuticals by 5.7% during the third quarter. Rhumbline Advisers now owns 70,705 shares of the biopharmaceutical company’s stock valued at $569,000 after buying an additional 3,803 shares during the period. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.